Silence Therapeutics Achieves $10M Milestone Payment From AstraZeneca Collaboration Following The Initiation Of Phase 1 Trial
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics plc (SLN) has received a $10M milestone payment from AstraZeneca following the initiation of a Phase 1 trial for the first product candidate under their siRNA collaboration. This marks the first clinical milestone in the partnership aimed at developing therapies for cardiovascular, renal, metabolic, and respiratory diseases. The collaboration, which began in March 2020, could see Silence receiving up to $140M in development milestones and $250M in commercialization milestones per target, with the deal covering up to ten targets.
February 23, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics receives a $10M milestone payment from AstraZeneca, marking a significant achievement in their collaboration.
The $10M milestone payment from AstraZeneca to Silence Therapeutics signifies a crucial step in their collaboration and could lead to further financial benefits for SLN as the partnership progresses. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in SLN's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
AstraZeneca initiates Phase 1 trial under its collaboration with Silence Therapeutics, focusing on developing siRNA therapeutics.
While the initiation of the Phase 1 trial is a positive development for AstraZeneca, reflecting progress in its collaboration with Silence Therapeutics, the financial impact is more significant for Silence due to the milestone payment. For AstraZeneca, this is part of its broader R&D efforts and may not have an immediate significant impact on its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80